- Home
- PRTG vs CANF Comparison
PRTG vs CANF Comparison
Compare PRTG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- CANF
- Stock Information
- Founded
- PRTG 1973
- CANF 1994
- Country
- PRTG British Virgin Islands
- CANF Israel
- Employees
- PRTG N/A
- CANF N/A
- Industry
- PRTG Oil & Gas Production
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- CANF Health Care
- Exchange
- PRTG Nasdaq
- CANF Nasdaq
- Market Cap
- PRTG 17.7M
- CANF 14.8M
- IPO Year
- PRTG N/A
- CANF N/A
- Fundamental
- Price
- PRTG $7.68
- CANF $1.04
- Analyst Decision
- PRTG
- CANF Strong Buy
- Analyst Count
- PRTG 0
- CANF 2
- Target Price
- PRTG N/A
- CANF $14.00
- AVG Volume (30 Days)
- PRTG 908.0K
- CANF 172.6K
- Earning Date
- PRTG 05-20-2025
- CANF 05-27-2025
- Dividend Yield
- PRTG N/A
- CANF N/A
- EPS Growth
- PRTG N/A
- CANF N/A
- EPS
- PRTG N/A
- CANF N/A
- Revenue
- PRTG N/A
- CANF $674,000.00
- Revenue This Year
- PRTG N/A
- CANF $461.72
- Revenue Next Year
- PRTG N/A
- CANF N/A
- P/E Ratio
- PRTG N/A
- CANF N/A
- Revenue Growth
- PRTG N/A
- CANF N/A
- 52 Week Low
- PRTG $2.10
- CANF $1.02
- 52 Week High
- PRTG $23.01
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- PRTG 46.45
- CANF 35.14
- Support Level
- PRTG $8.11
- CANF $1.07
- Resistance Level
- PRTG $9.34
- CANF $1.14
- Average True Range (ATR)
- PRTG 1.19
- CANF 0.06
- MACD
- PRTG -0.42
- CANF 0.01
- Stochastic Oscillator
- PRTG 5.00
- CANF 21.43
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).